- Home
- IRT vs RNA Comparison
IRT vs RNA Comparison
Compare IRT & RNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IRT
- RNA
- Stock Information
- Founded
- IRT 2009
- RNA 2012
- Country
- IRT United States
- RNA United States
- Employees
- IRT N/A
- RNA N/A
- Industry
- IRT Real Estate Investment Trusts
- RNA Biotechnology: Pharmaceutical Preparations
- Sector
- IRT Real Estate
- RNA Health Care
- Exchange
- IRT Nasdaq
- RNA Nasdaq
- Market Cap
- IRT 4.3B
- RNA 4.4B
- IPO Year
- IRT 2013
- RNA 2020
- Fundamental
- Price
- IRT $17.73
- RNA $29.31
- Analyst Decision
- IRT Buy
- RNA Strong Buy
- Analyst Count
- IRT 10
- RNA 14
- Target Price
- IRT $22.70
- RNA $68.00
- AVG Volume (30 Days)
- IRT 1.9M
- RNA 1.4M
- Earning Date
- IRT 07-30-2025
- RNA 08-08-2025
- Dividend Yield
- IRT 3.84%
- RNA N/A
- EPS Growth
- IRT N/A
- RNA N/A
- EPS
- IRT 0.13
- RNA N/A
- Revenue
- IRT $641,330,000.00
- RNA $8,927,000.00
- Revenue This Year
- IRT $5.23
- RNA N/A
- Revenue Next Year
- IRT $6.20
- RNA $155.06
- P/E Ratio
- IRT $136.48
- RNA N/A
- Revenue Growth
- IRT N/A
- RNA N/A
- 52 Week Low
- IRT $17.10
- RNA $21.51
- 52 Week High
- IRT $22.26
- RNA $56.00
- Technical
- Relative Strength Index (RSI)
- IRT 35.61
- RNA 42.04
- Support Level
- IRT $17.74
- RNA $31.59
- Resistance Level
- IRT $18.02
- RNA $38.00
- Average True Range (ATR)
- IRT 0.37
- RNA 2.01
- MACD
- IRT -0.04
- RNA -0.59
- Stochastic Oscillator
- IRT 10.22
- RNA 9.67
About IRT Independence Realty Trust Inc.
Independence Realty Trust Inc is a real estate investment trust (REIT) that acquires, owns, operates, improves and manages multifamily apartment communities across non-gateway U.S. markets. It owns and operates multifamily apartment properties, across non-gateway U.S markets, including Louisville, Memphis, Atlanta, and Raleigh. The company is focused on gaining scale within key amenity-rich submarkets that offer school districts, retail, and various employment centers.
About RNA Avidity Biosciences Inc.
Avidity Biosciences Inc is a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates, or AOCs. Company's pipeline currently has three programs in potentially registrational clinical trials: DM1, FSHD, and DMD. The segments includes following: Del-zota for DMD44, Del-desiran for DM1, Del-brax for FSHD.